Literature DB >> 24836333

Osteoporosis and fragility fractures: Vertebral fractures.

Paul Gerdhem1.   

Abstract

The incidence of vertebral fragility fractures and deformity increase steeply with age. Every sixth woman and every twelfth man will sustain a symptomatic vertebral fracture. Vertebral fractures result in pain, functional disability and decreased quality of life, which may last for several years, and may also affect mortality. The patient with an acute fracture should be examined with radiology for diagnosis. In case of a low-energy fracture, osteoporosis should be suspected and investigated. If the pain management fails, vertebroplasty or kyphoplasty could be considered. Braces may be used, but evidence for its effect is lacking. In the rare event of neurological compromise, or unstable fractures, surgical treatment should be considered. After vertebral fragility fractures, the risk for new fractures is high and secondary preventive measures advocated. The best evidence for secondary prevention is currently on medical treatment of osteoporosis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Treatment; Vertebral fracture

Mesh:

Year:  2013        PMID: 24836333     DOI: 10.1016/j.berh.2014.01.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  26 in total

1.  Thoracolumbar fascia injury associated with residual back pain after percutaneous vertebroplasty: a compelling study.

Authors:  Z Guo; J Yang; Y Zheng; Y Wang
Journal:  Osteoporos Int       Date:  2015-06-06       Impact factor: 4.507

2.  A survey of outcomes and management of patients post fragility fractures in China.

Authors:  O Wang; Y Hu; S Gong; Q Xue; Z Deng; L Wang; H Liu; H Tang; X Guo; J Chen; X Jia; Y Xu; L Lan; C Lei; H Dong; G Yuan; Q Fu; Y Wei; W Xia; L Xu
Journal:  Osteoporos Int       Date:  2015-05-13       Impact factor: 4.507

3.  Clinical management of osteoporotic vertebral fracture treated with percutaneous vertebroplasty.

Authors:  Anna Capozzi; Giovanni Scambia; Alessandro Pedicelli; Maurizio Evangelista; Roberto Sorge; Stefano Lello
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

4.  Low-dose diclofenac in patients with fragility fractures.

Authors:  Letizia Vannucci; Caterina Fossi; Giorgio Gronchi; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

Review 5.  Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.

Authors:  Bente Langdahl; Serge Ferrari; David W Dempster
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-05       Impact factor: 5.346

6.  The Impact of Prior Fragility Fractures on Complications After Total Hip Arthroplasty: A Propensity Score-Matched Cohort Study.

Authors:  Austin J Ross; Bailey J Ross; Olivia C Lee; George N Guild; William F Sherman
Journal:  Arthroplast Today       Date:  2021-08-19

7.  Vertebral body morphology is associated with incident lumbar vertebral fracture in postmenopausal women. The OFELY study.

Authors:  J P Roux; S Belghali; J Wegrzyn; E S Rendu; R Chapurlat
Journal:  Osteoporos Int       Date:  2016-03-08       Impact factor: 4.507

8.  Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.

Authors:  Adele L Boskey; Eve Donnelly; Elizabeth Boskey; Lyudmila Spevak; Yan Ma; Wei Zhang; Joan Lappe; Robert R Recker
Journal:  J Bone Miner Res       Date:  2015-12-24       Impact factor: 6.741

9.  Long-term experiences of pain after a fragility fracture.

Authors:  A Gheorghita; F Webster; S Thielke; J E M Sale
Journal:  Osteoporos Int       Date:  2018-02-17       Impact factor: 4.507

Review 10.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.